LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 15 of 15: Calculated dose-response metrics. - Dataset (ID:20252)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | GR_AOC |
---|---|---|
MDA-MB-231 | WYE-125132 | 0.7072 |
MDA-MB-231 | WZ-4-145 | 0.3146 |
MDA-MB-231 | WZ3105 | 1.2276 |
MDA-MB-231 | XL147 | -0.0157 |
MDA-MB-231 | XMD11-50 | 0.5106 |
MDA-MB-231 | XMD11-85h | 0.2159 |
MDA-MB-231 | XMD16-144 | 0.8949 |
MDA-MB-231 | Y39983 | 0.3522 |
MDA-MB-231 | YM 201636 | 0.2413 |
MDA-MB-231 | ZSTK474 | 0.3310 |
SK-BR-3 | Seliciclib | 0.1709 |
SK-BR-3 | A443654 | 1.2708 |
SK-BR-3 | Afatinib | 1.1205 |
SK-BR-3 | AT-7519 | 1.1234 |
SK-BR-3 | AZD 5438 | 0.8629 |
SK-BR-3 | AZD-6482 | 0.2743 |
SK-BR-3 | AZD7762 | 1.2165 |
SK-BR-3 | AZD8055 | 1.1417 |
SK-BR-3 | AZD8330 | 0.2909 |
SK-BR-3 | Barasertib | 1.0762 |
SK-BR-3 | Dactolisib | 1.0156 |
SK-BR-3 | BI-2536 | 1.1731 |
SK-BR-3 | SNS-032 | 1.2444 |
SK-BR-3 | BMS345541 | 0.3900 |
SK-BR-3 | Brivanib | 0.1634 |